仙特敏治疗慢性荨麻疹的临床效观察

仙特敏治疗慢性荨麻疹疹４０例，对照组３３例用息斯敏治疗，结果示：治疗组疹愈率为４５％，总有效率为９２．５％，疹愈率为２１．２％，总有效率为６９．１％，通过二组对照观察表明，仙特敏组疗明显优于息斯敏组，经统计学检验，二者间有显著性差异（Ｐ＜０．０１）。     

甲真菌病病原菌流行病学变迁趋势

报道仙特敏、甲氰咪哌和潘生丁联合应用治疗５７例慢性荨麻疹的疗效观察。结果：联合组显效率 率和总有效率分别为７９％和９１．２％，仙特敏单用组显效率和总有效率分别为５１．４％和７７．１％，两组比较有显著差异（Ｐ＜０．００１）。本文提示这三种药联用是治疗慢性荨麻疹安全和有效的方法。     

氨甲苯酸治疗变应性皮肤疗疗效观察

本文报告用氨甲苯酸治疗变应性皮肤病６８例，对照组５０例用硫代硫酸钠治疗。治疗组痊愈率４５．５８％，总有效率９２．６４％，对照组痊愈率２４％，总有效率８６％。结果经统计学检验，氨甲苯酸治疗变应性皮肤病治愈率与对照组差异有显著性。     

环丙沙星霜治疗化脓性皮肤病临床观察

采用分组对照观察环丙沙星霜（ＣＩＰ）外用治疗化脓性皮肤病。ＣＩＰ组患者１１３例，痊愈８５例，显著进步１６例，痊愈率７５．２％，总有效率８９．４％；新霉素软膏（ＮＭ）组６３例，痊愈３２例，显著进步１４例，痊愈率５０．８％，总有效率７３．０２％；治疗组的痊愈率和总有效率显著高于对照组（Ｐ＜０．０１）。两组未见明显副作用。同时还对患者进行了细菌培养和药敏试验及ＣＩＰ最小抑菌药物浓度（ＭＩＣ）试验。     

特丽仙痤疮液治疗寻常痤疮20例临床观察报告

以特丽仙痤疮液（磷酸氯洁霉素）治疗寻常痤疮２０例，复方硫磺洗剂治疗寻常痤疮２０例作为对照组，结果发现总有效率治疗组（为９５％）优于对照组（为７０％）。     

特丽仙痤疹液治疗寻常痤疮20例临床观察报告

以特丽仙痤疮液治疗寻常痤疹２０例，复方硫磺洗剂治疗寻常痤疹２０例作为对照组；结果发现总有效率治疗组（为９５％）优于对照组（为７０％）。     

仙特敏、甲氰咪呱和潘生丁联合治疗慢性荨麻疹疗效观察

报道仙特敏、甲氰咪呱和潘生丁联合应用治疗５７例慢性荨麻疹的疗效观察。结果：联合组显效率和总有效率分别为７９％和９１．２％，仙特敏单用组显效率和总有效率分别为５１．４％和７７．１％，两组比较有显著性差异（Ｐ＜０．００１）。本文提示这三种药联用是治疗慢性荨麻疹安全和有效的方法。     

异维A酸联合喷昔洛韦乳膏治疗扁平疣40例

目的：观察异维A酸与喷昔洛韦乳膏治疗扁平疣的临床疗效。方法：随机将扁平疣患者70例分治疗组40例、对照组30例。治疗组口服异维A酸10mg，每日2次，2周后改用每日1次，同时每日外用喷昔落韦乳膏2次，疗程4周；对照组单纯每日外用喷昔落韦乳膏2次，疗程4周。结果：治疗组痊愈率为70％，总有效率85％，对照组痊愈率为40％，总有效率56．7％，两组痊愈率、总有效率比较均有显著性差异（P〈0．05）。结论：异维A酸联合喷昔洛韦乳膏治疗扁平疣有效。     

β—干扰素治疗尖锐湿疣疗效观察

目的 评价 β－干扰素治疗尖锐湿疣的疗效、安全性及复发率。方法 采用随机对照的方法，治疗组采用β－干扰素肌肉注射，同时β－干扰素霜外用；对照组采用安慰剂生理盐水肌肉注射，同时β－干扰素霜外用。结果 治疗组痊愈率５１．２８％，总有效率为６４．１０％，对照组痊愈率２３．３３％，总有效率３６．６７％。结论 选用β－干扰素治疗皮损小而少的尖脱湿疣患者，安全有效。     

曲尼司特治疗特应性皮炎临床疗效观察

目的：观察曲尼司特治疗特应性皮炎的疗效与安全性。方法：采用随机双盲、安慰剂平行对照的方法，将入选患者随机分为试验组与对照组，分别接受曲尼司特和安慰剂的治疗，同时两组患者均外用丝塔芙保湿润肤霜。对皮肤病变范围、皮损严重程度、瘙痒和睡眠影响程度进行临床观察，用SCORAD评分系统进行评估。结果：治疗组23例基本痊愈6例，显效9例，有效4例，无效4例，总有效率为65．22％，对照组总有效率为22．73％，两组有显著性差异（P=0．0216）；治疗组患者治疗前后SCORAD评分有统计学差异（P〈0．05）。治疗过程中治疗组不良反应仅为4．35％，且症状轻。结论：曲尼司特治疗特应性皮炎安全、有效。     

New fillers for the new man

ABSTRACT:  Two new collagen-based lidocaine-containing dermal fillers, ArteSense™/ArteFill™ (Artes Medical, San Diego, CA) and Evolence® (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill™ has been available in the United States since 2006, and it is expected that Evolence® will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.     

Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients

It is generally believed that ablative laser therapies result in prolonged healing and greater adverse events when compared with nonablative lasers for skin resurfacing. To evaluate the efficacy of ablative laser use for skin resurfacing and adverse events as a consequence of treatment in comparison to other modalities, a PRISMA‐compliant systematic review (Systematic Review Registration Number: 204016) of twelve electronic databases was conducted for the terms “ablative laser” and “skin resurfacing” from March 2002 until July 2020. Studies included meta‐analyses, randomized control trials, cohort studies, and case reports to facilitate evaluation of the data. All articles were evaluated for bias. The search strategy produced 34 studies. Of 1093 patients included in the studies of interest, adverse events were reported in a total of 106 patients (9.7%). Higher rates of adverse events were described in nonablative therapies (12.2% ± 2.19%, 31 events) when compared with ablative therapy (8.28% ± 2.46%, 81 events). 147 patients (13.4%) reported no side effects, 68 (6.22%) reported expected, transient self‐resolving events, and five (0.046%) presented with hypertrophic scarring. Excluding transient events, ablative lasers had fewer complications overall when compared with nonablative lasers (2.56% ± 2.19% vs 7.48% ± 3.29%). This systematic review suggests ablative laser use for skin resurfacing is a safe and effective modality to treat a range of pathologies from photodamage and acne scars to hidradenitis suppurativa and posttraumatic scarring from basal cell carcinoma excision. Further studies are needed, but these results suggest that ablative lasers are a superior, safe, and effective modality to treat damaged skin.     

Deutliche Einschränkung der Lebensqualität bei Patienten mit Pemphigus vulgaris: Ergebnisse der deutschen Bullous Skin Disease (BSD)‐Studiengruppe

Background: Pemphigus vulgaris is a potentially life‐threatening autoimmune disorder of the skin and mucous membranes characterized by antibodies against epidermal adhesion molecules. Clinically characteristic are painful chronic blisters or erosions of mucous membranes and skin. There are no published studies on the impact o this disease on quality of life. Patients and methods: This registration was performed within the scope of the German BSD (Bullous Skin Disease) study group, from November 1997 until January 2002. A total of 36 patients with the first diagnosis of pemphigus vulgaris were registered at the university hospitals of Dresden, Erlangen, Kiel, Mannheim, München and Würzburg. Thirty of the 36 (83 %) patients participated in the quality of life questionnaire utilizing the German version of ‘Dermatology Life Quality Index’ (DLQI) provided by A. Y. Finlay. The DLQI varies from 0 to 30 with an increased DLQI score indicating a decrease in quality of quality. Results: The overall DLQI total score of 10 ± 6,7 in the investigated pemphigus patients was significantly increased in comparison to other skin diseases. Conclusions: These results suggest that the DLQI can be a very useful additional outcome criteria for clinical studies with pemphigus vulgaris and in the treatment of these patients.     

Genetic alterations in RAS‐regulated pathway in acral lentiginous melanoma

Studies integrating clinicopathological and genetic features have revealed distinct patterns of genomic aberrations in Melanoma. Distributions of BRAF or NRAS mutations and gains of several oncogenes differ among melanoma subgroups, while 9p21 deletions are found in all melanoma subtypes. In the study, status of genes involved in cell cycle progression and apoptosis was evaluated in a panel of 17 frozen primary acral melanomas. NRAS mutations were found in 17% of the tumors. In contrast, BRAF mutations were not found. Gains of AURKA gene (20q13.3) were detected in 37.5% of samples, gains of CCND1 gene (11q13) or TERT gene (5p15.33) in 31.2% and gains of NRAS gene (1p13.2) in 25%. Alterations in 9p21 were identified in 69% of tumors. Gains of 11q13 and 20q13 were mutually exclusive, and 1p13.2 gain was associated with 5p15.33. Our findings showed that alterations in RAS‐related pathways are present in 87.5% of acral lentiginous melanomas.     

Mutations in mevalonate pathway genes in patients with familial or sporadic porokeratosis

Porokeratosis comprises heterogeneous keratinization disorders that are characterized by one or more atrophic patches surrounded by a ridge‐like cornoid lamella. In this study, we evaluated seven families affected by porokeratosis and five sporadic patients of the disease in a Chinese population. We performed Sanger sequencing of exons and flanking intron–exon boundaries of mevalonate pathway genes (MVD, MVK, PMVK and FDPS) and of SLC17A9. In five familial and three sporadic patients, we detected six variations, including four novel mutations (MVD c.1A>G; p.Met1?, c.916G>A; p.Ala306Thr, c.1013+1G>A, and PMVK c.65A>G; p.Lys22Arg) and two recurrent mutations (MVD c.746T>C; p.Phe249Ser, and MVK c.1028T>C; p.Leu343Pro). We then applied I‐TASSER and iGEMDOCK to assess these variants for probable functional impacts. The findings of this study extend the mutation spectrum of porokeratosis and provide further evidence for the genetic basis of this disease.     

Occupational allergic contact dermatitis caused by decorative plants

12 cases of occupational allergic contact dermatitis caused by decorative plants were diagnosed in a 14-year period. The patients were middle-aged, and their average exposure time was 13 years. The plant families and plants causing occupational contact dermatitis were Compositae (5 patients: chrysanthemum, elecampane, gerbera, feverfew), Alstroemeriaceae (5 patients, Alstroemeria ), Liliaceae (4 patients; tulip, hyacinth). Amaryllidaceae (2 patients: narcissus) and Caryophyllaceae (2 patients; carnation, cauzeflower). The known chemical allergens causing dermatitis were tuliposide-A and sesquiterepene lactones, such as alantolactones and parthenolide, in the Liliaceae and Compositae families. 7 of the 12 patients were able to continue their work; 5 were not because of severe relapses of skin symptoms. The plant allergen and extract series currently available are of great help in the diagnosis.